Clinical Laserthermia Systems AB announces that the date for conversion of interim shares is estimated to 15 March 2023
Lund, Sweden March 10, 2023 – Clinical Laserthermia Systems AB (“CLS” or the “Company”) can today announce that 25,315,836 new B-shares have been registered with the Swedish Companies Registration Office, as a result of the exercise of warrants of series TO 5 B (“TO 5 B”).
Conversion of interim shares to ordinary B-shares takes place around 15 March 2023 and are expected to be available on each subscriber's account around 17 March 2023. The total number of shares in the Company as a result of the warrant exercise of TO 5 B and the directed share issue to underwriters in connection with TO 5 B amount to 162,844,439, of which 600,000 A-shares and 162,244,439 B-shares, and the share capital will amount to approximately SEK 15,063,110.7.
For information about the warrants of series TO 5 B, please contact:
Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10
E-mail: cf@sedermera.se
For more information about CLS, please contact:
Dan J Mogren, CEO Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, The Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: www.clinicallaser.se